Research supporting Precise Sciences screening and earlier detection efforts encompass a Cologuard® (mt-sDNA) modeling research in collaboration with Mayo Clinic to evaluate the impression of sessile serrated polyps on predicted colorectal most cancers outcomes with Cologuard or FIT screening1, and medical analysis from Thrive that emphasizes the necessity for integrating a multi-cancer screening take a look at into the usual of care2.

Information being introduced on the Oncotype DX® take a look at portfolio embody a brand new evaluation, based mostly on first outcomes from the impartial RxPONDER research, that reinforce the cost-effectiveness of the Oncotype DX Breast Recurrence Rating® take a look at in node-positive early-stage breast most cancers3; an oral presentation from the West German Examine Group (WSG) on the potential section III ADAPT research which used the Oncotype DX take a look at to stratify sufferers with early-stage breast most cancers4; and outcomes from a patient-specific meta-analysis of three validation research of the Oncotype DX Colon Recurrence Rating take a look at5.

Additionally being introduced are findings from Metropolis of Hope’s Heart for Precision Medication that emphasize a complete sequencing method to assist information most cancers therapy and assess danger for most cancers and non-cancer ailments, utilizing Precise Sciences’ GEM ExTra® panel6, and early research outcomes from PFS Genomics Inc., a improvement stage firm based by radiation oncologists, not too long ago acquired by Precise Sciences. PFS Genomics has recognized a gene expression signature, named Profile for the Omission of Native Adjuvant. Radiation (POLAR), to foretell whether or not girls with early-stage invasive breast most cancers, handled with breast conserving surgical procedure, are more likely to profit from radiotherapy7.

Following are the seven abstracts which have been accepted on the 2021 ASCO Annual Assembly. The on-demand supplies, together with posters, might be accessible within the ASCO Meeting Library, beginning at 9:00AM EDT on June 4, 2021.

Affect of the Sessile Serrated Polyp Pathway on Predicted Colorectal Most cancers Outcomes within the CRC-AIM Mannequin
Authors: Kisiel, J., et al.
Session: Prevention, Threat Discount, and Hereditary Most cancers
Summary Quantity: 10545

Most cancers screening utilization in sufferers recognized with most cancers varieties with and with out beneficial screening modalities 
Authors: Cohain, A., et al.
Session: Prevention, Threat Discount, and Hereditary Most cancers
Summary Quantity: 10557

Using business medical health insurance claims knowledge to determine the impression of most cancers screening and estimate the additional advantage of a multi-cancer liquid biopsy ordered throughout routine bodily exams
Authors: Cohain, A., Hathaway, C., et al.
Session: Publication Solely: Prevention, Threat Discount, and Hereditary Most cancers
Summary Quantity: e22516

Value-effectiveness of Oncotype DX Breast Recurrence Rating take a look at in postmenopausal girls with node-positive early breast most cancers based mostly on the RxPONDER trial
Authors: Berdunov, V., et al.
Session: Breast Most cancers – Native/Regional/Adjuvant
Summary Quantity: 534

Prognostic impression of Recurrence Rating, endocrine response and clinical-pathological elements in high-risk luminal breast most cancers: Outcomes from the WSG-ADAPT HR+/HER2- chemotherapy trial
Authors: Gluz, O., et. al
Session: Breast Most cancers – Native/Regional/Adjuvant
Summary Quantity: 504; Oral presentation on June 6, 2021 at 8 AM EDT.

Discovery and validation of a genomic signature to determine girls with early-stage invasive breast most cancers who might safely omit adjuvant radiotherapy after breast-conserving surgical procedure
Authors: Sjöström, M., et al.
Session: Breast Most cancers – Native/Regional/Adjuvant
Summary Quantity: 512

Affected person-specific meta-analysis of three validation research of the 12-gene Colon Most cancers Recurrence Rating Assay for recurrence danger evaluation after surgical procedure with or with out 5FU and oxaliplatin.
Authors: Yothers, G., et al.
Session: Gastrointestinal Most cancers – Colorectal and Anal
Summary Quantity: 3599

Potential genomic testing of unselected most cancers sufferers yields insights about most cancers susceptibility and non-cancer illness with therapeutic implications
Authors: Grey, S., et al
Session: Prevention, Threat Discount, and Hereditary Most cancers
Summary Quantity: 10603

# # #

About Precise Sciences Corp.
A number one supplier of most cancers screening and diagnostic checks, Precise Sciences relentlessly pursues smarter solutions to offer individuals the readability to take life-changing motion, earlier. Constructing on the success of Cologuard® and Oncotype® checks, Precise Sciences is investing in its product pipeline to help sufferers all through their most cancers prognosis and therapy. Precise Sciences unites visionary collaborators to assist advance the battle towards most cancers. For extra info, please go to the corporate’s web site at  www.exactsciences.com, observe Precise Sciences on Twitter @ExactSciences, or discover Exact Sciences on Fb.

NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Rating, Oncotype DX Breast DCIS Rating, Oncotype DX Genomic Prostate Rating, Oncotype MAP Pan-Most cancers Tissue, and Oncotype DX AR-V7 Nucleus Detect are emblems or registered emblems of Genomic Well being, Inc. Precise Sciences and Cologuard are emblems or registered emblems of Precise Sciences Company. GEM ExTra is a registered trademark of Ashion Analytics, LLC, an Precise Sciences Firm. All different emblems and repair marks are the property of their respective house owners. 

Ahead-Trying Statements
This information launch comprises forward-looking statements regarding our expectations, anticipations, intentions, beliefs, or methods relating to the longer term.  These forward-looking statements are based mostly on assumptions that we now have made as of the date hereof and are topic to recognized and unknown dangers and uncertainties that might trigger precise outcomes, situations, and occasions to vary materially from these anticipated. You shouldn’t place undue reliance on forward-looking statements. There may be no assurance that we will (i) notice the anticipated profit from the acquisition of PFS Genomics or (ii) efficiently develop or commercialize any services or products using PFS Genomics’ expertise. Dangers and uncertainties that will have an effect on our forward-looking statements are described within the Threat Components sections of our most up-to-date Annual Report on Kind 10-Okay and any subsequent Quarterly Reviews on Kind 10-Q, and in our different stories filed with the Securities and Trade Fee. We undertake no obligation to publicly replace any forward-looking assertion, whether or not written or oral, which may be made every so often, whether or not because of new info, future developments or in any other case.

____________________

1 Kisiel, J., et al. Summary #10545, ASCO 2021.

2 Cohain, A., et al. Abstracts #10557 & e22516, ASCO 2021.

3 Berdunov V. et al. Summary #534, ASCO 2021.

4 Gluz, O., et. Al. Summary #504, ASCO 2021.

5 Yothers, G., et al. Summary #3599, ASCO 2021.

6 Grey, S., et al. Summary #10603, ASCO 2021.

7 Sjöström, M., et al. Summary #512, ASCO 2021.

SOURCE EXACT SCIENCES CORP

Associated Hyperlinks

http://www.exactsciences.com





Source link